Peptide status
by country.

What KPV resolves to

KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.

Evidence lane

FDA-reviewed unapproved peptide identity

Current record

No FDA-approved KPV drug and no identified human administration study

Checked

July 20, 2026